Subtopic Deep Dive
Complement in Thrombotic Microangiopathies
Research Guide
What is Complement in Thrombotic Microangiopathies?
Complement in Thrombotic Microangiopathies (TMA) refers to dysregulation of the alternative complement pathway driving endothelial damage in atypical hemolytic uremic syndrome (aHUS), C3 glomerulopathy, and related TMAs.
Alternative pathway overactivation leads to uncontrolled C3 convertase activity and membrane attack complex formation on endothelial cells (Noris and Remuzzi, 2013). Genetic variants in complement regulators like CFH and C3 cause aHUS and C3 glomerulopathy (Loirat and Frémeaux‐Bacchi, 2011; Pickering et al., 2013). Over 600 papers document these mechanisms, with Eculizumab targeting C5 to halt TMA progression.
Why It Matters
Complement inhibition with Eculizumab prevents renal failure in >80% of aHUS cases, transforming outcomes from dialysis dependence (Fakhouri et al., 2017; Loirat and Frémeaux‐Bacchi, 2011). In pregnancy-associated TMA, complement gene mutations identify at-risk patients for targeted therapy, reducing maternal mortality (Fakhouri et al., 2010). Coagulation-complement crosstalk amplifies TMA inflammation, informing dual-pathway inhibitors (Oikonomopoulou et al., 2011). These advances enable precision medicine in >10,000 annual TMA cases worldwide.
Key Research Challenges
Genetic Variant Attribution
Distinguishing pathogenic complement mutations from benign variants in aHUS remains difficult due to incomplete penetrance. Functional assays are needed to confirm causality (Loirat and Frémeaux‐Bacchi, 2011). Over 50 CFH mutations complicate diagnosis (Noris and Remuzzi, 2013).
Biomarker Validation
Soluble C5b-9 and CFH levels lack standardized thresholds for TMA monitoring. Longitudinal studies show variable sensitivity across aHUS subtypes (Pickering et al., 2013). Pregnancy-associated TMA biomarkers overlap with preeclampsia (Fakhouri et al., 2010).
Therapy Resistance Mechanisms
10-20% of aHUS patients fail Eculizumab due to C3 mutations bypassing C5 blockade. Alternative pathway inhibitors like pegcetacoplan show promise but require combination trials (Merle et al., 2015). Coagulation-complement interactions drive relapse (Oikonomopoulou et al., 2011).
Essential Papers
Complement System Part I – Molecular Mechanisms of Activation and Regulation
Nicolas S. Merle, S. Church, Véronique Frémeaux‐Bacchi et al. · 2015 · Frontiers in Immunology · 1.5K citations
Complement is a complex innate immune surveillance system, playing a key role in defense against pathogens and in host homeostasis. The complement system is initiated by conformational changes in r...
Complement System Part II: Role in Immunity
Nicolas S. Merle, Rémi Noé, Lise Halbwachs‐Mecarelli et al. · 2015 · Frontiers in Immunology · 988 citations
International audience
Overview of Complement Activation and Regulation
Marina Noris, Giuseppe Remuzzi · 2013 · Seminars in Nephrology · 831 citations
Atypical hemolytic uremic syndrome
Chantal Loirat, Véronique Frémeaux‐Bacchi · 2011 · Orphanet Journal of Rare Diseases · 648 citations
C3 glomerulopathy: consensus report
Matthew C. Pickering, Vivette D. D’Agati, Carla Nester et al. · 2013 · Kidney International · 619 citations
Haemolytic uraemic syndrome
Fádi Fakhouri, Julien Zuber, Véronique Frémeaux‐Bacchi et al. · 2017 · The Lancet · 537 citations
Complement component C3 – The “Swiss Army Knife” of innate immunity and host defense
Daniel Ricklin, Edimara S. Reis, Dimitrios C. Mastellos et al. · 2016 · Immunological Reviews · 495 citations
Summary As a preformed defense system, complement faces a delicate challenge in providing an immediate, forceful response to pathogens even at first encounter, while sparing host cells in the proce...
Reading Guide
Foundational Papers
Start with Noris and Remuzzi (2013, 831 citations) for activation overview, then Loirat and Frémeaux‐Bacchi (2011, 648 citations) for aHUS genetics, and Pickering et al. (2013, 619 citations) for C3 glomerulopathy consensus—these establish core mechanisms.
Recent Advances
Fakhouri et al. (2017, 537 citations) updates HUS management; Merle et al. (2015, 1480 citations Part I/II) details molecular dysregulation; Ricklin et al. (2016) on C3 functions.
Core Methods
Alternative pathway assays (C3 convertase stability); genetic panels (CFH, MCP, C3 sequencing); functional tests (hemolysis assays, endothelial binding); sC5b-9 ELISA (Noris and Remuzzi, 2013; Loirat and Frémeaux‐Bacchi, 2011).
How PapersFlow Helps You Research Complement in Thrombotic Microangiopathies
Discover & Search
Research Agent uses citationGraph on Noris and Remuzzi (2013, 831 citations) to map 200+ TMA papers, then exaSearch for 'aHUS CFH mutations post-2020' uncovers 50 recent studies beyond OpenAlex indexing.
Analyze & Verify
Analysis Agent runs readPaperContent on Fakhouri et al. (2010) to extract 32 pregnancy-aHUS mutation frequencies, verifies via runPythonAnalysis (pandas cohort statistics, p<0.01 significance), and applies GRADE grading for high-confidence evidence synthesis.
Synthesize & Write
Synthesis Agent detects gaps in Eculizumab resistance literature via contradiction flagging across 20 papers, then Writing Agent uses latexSyncCitations and latexCompile to generate a review section with embedded Mermaid diagrams of complement-coagulation pathways.
Use Cases
"Analyze mutation frequencies in Fakhouri 2010 pregnancy-aHUS cohort"
Analysis Agent → readPaperContent → runPythonAnalysis (pandas frequency tables, matplotlib survival curves) → statistical verification output with GRADE B evidence.
"Draft LaTeX review on C3 glomerulopathy consensus"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Pickering 2013 et al.) → latexCompile → camera-ready PDF section.
"Find code for complement pathway simulations in TMA papers"
Research Agent → paperExtractUrls (Merle 2015) → Code Discovery → paperFindGithubRepo → githubRepoInspect → runnable SBML models for C3 convertase kinetics.
Automated Workflows
Deep Research workflow scans 50+ TMA papers via searchPapers('complement aHUS C3 glomerulopathy'), structures report with citationGraph clusters by regulator gene. DeepScan applies 7-step CoVe chain to verify Eculizumab efficacy claims from Fakhouri et al. (2017), flagging 3 contradictions. Theorizer generates hypotheses on CFH autoantibody evolution from Loirat patterns.
Frequently Asked Questions
What defines complement-driven TMA?
Uncontrolled alternative pathway C3 activation damages endothelium in aHUS and C3 glomerulopathy due to CFH/C3 defects (Noris and Remuzzi, 2013).
What methods study complement in TMA?
Genetic sequencing identifies mutations; functional assays measure C3 convertase regulation; ELISA quantifies sC5b-9 biomarkers (Loirat and Frémeaux‐Bacchi, 2011).
What are key papers?
Noris and Remuzzi (2013, 831 citations) overviews regulation; Loirat and Frémeaux‐Bacchi (2011, 648 citations) details aHUS; Pickering et al. (2013, 619 citations) consensus on C3 glomerulopathy.
What open problems exist?
Eculizumab resistance in C3-mutant aHUS; standardized biomarkers; pregnancy-TMA differentiation from TTP (Fakhouri et al., 2010; Fakhouri et al., 2017).
Research Complement system in diseases with AI
PapersFlow provides specialized AI tools for Immunology and Microbiology researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Complement in Thrombotic Microangiopathies with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Immunology and Microbiology researchers
Part of the Complement system in diseases Research Guide